Effect of the Chemoprotective Agent WR-2721 on Disposition and Biotransformations of Ormaplatin in the Fischer 344 Rat Bearing a Fibrosarcoma1
Total Page:16
File Type:pdf, Size:1020Kb
[CANCERRESEARCH55, 2837—2846,July1. 1995] Effect of the Chemoprotective Agent WR-2721 on Disposition and Biotransformations of Ormaplatin in the Fischer 344 Rat Bearing a Fibrosarcoma1 D. CharlesThompson,StevenD. Wyrick, David J. Holbrook, and StephenG. Chane? Curriculum in Toxicology (D. C. T.. D. J. H., S. G. C.] and Department of Biochemistry and Biophysics ID. J. H., S. G. CI, School of Medicine, and Division of Medicinal Chemistry and Natural Products [S. D. WI, School of Pharmacy, University ofNorth Carolina, Chapel Hill, North Carolina 27599-7260 ABSTRA4@T be selective for nontumor tissues (4, 5). The proposed mechanism for this selectivity is a relative lack of alkaline phosphatase activity in The effects of the phosphorothloate agent, WR-2721, have been Eaves tumor tissues as compared to normal tissues and the lesser conversion ligated with respect to the biotransformations oformaplatin in the Fischer of the inactive parent compound, WR-2721, to its postulated active 344 rat bearinga transplantedfibrosarcoma.A number of different paradigms ofdosing route and schedule for the administration of the two thiol metabolite, WR-1065, within tumor tissues. Because WR-1065 agents have been investigated. In the first group ofexperiments, WR.2721 is postulated to bind to reactive platinum species within the cell, this (200mg/kg, l.p.) wasadministered30 mis beforeormaplatin (12.5mg/kg, would provide a mechanistic basis for selective protection of normal i.p.), and then peritoneal fluid, plasma, and tissues were harvested at 30 tissues as compared to tumor tissues (3, 6, 7). This hypothesis has mm after the ormaplatin administration. Our results suggest that a sig never been tested directly. Ormaplatin (formerly tetraplatin) is a nificant interaction between WR-2721 and ormaplatin is occurring in the platinum(IV) analogue of cisplatin recently in Phase I clinical trials @tonea1cavity.The interaction was evident in terms of both effects on (8—10).This laboratory has previously reported investigations of the distribution and disposition of total platinum and in alterations of the biotransformations of ormaplatin under a variety of conditions in vitro profilesof biotransformation products formed in the various tissues and (1 1), in cell culture (12, 13), and in vivo (14—16).These studies have fluids. Plasma protein binding oformaplatin was decreased by 50% in the shown that ormaplatin is very rapidly (t½‘@3s) reduced to the presence ofWR-2721. Total platinum in the spleen was decreased by 66% and In the liver by 50%. There were no trends among the findings that corresponding platinum(II) complex, Pt(dach)C12, in the presence of would indicate any selectivity between tumor and nontumor tissue with plasma protein sulfhydryl (1 1), and that subsequent biotransforma respect to the effects of WR-2721 on the parameters measured. Subse tions of this complex appear to be similar to those reported for quent investigations examined the effects of dosing the WR-2721 by the cisplatin (17, 18). The previous studies have also shown that the LV. rOute while continuing with the i.p. administration of the ormaplatin. intracellular biotransformations of ormaplatin in vivo are very similar WR-2721 was administered either 30 or 5 mm before the ormaplatin, and in all tissues examined to date (19). The present report discusses the plasma and tissues were harvested at 15, 30, or 60 mm after ormapla investigations into the effects of WR-2721 on ormaplatin biotransfor tin administration. The reverse-phase HPLC peak, which behaved chro mations in tumor-bearing male rats as a direct test of the proposed matographically as a Pt(dach)(WR-1065) standard, was less prominent mechanism of action of WR-2721. after the Lv. administration of WR-2721 than It was after i.p. administra lion under any of the paradigms tested. There was again no evidence for selectivity between tumor and nontumor tissue in the findings from any of MATERIALS AND METHODS the paradigms. It is concluded that If WR-2721 is capable of selectively protecting nontumor tissue from the toxicities of platinum-based chemo Materials. [4,5-3H2(n)]Ormaplatin (formerly tetraplatin) was prepared in therapy, It is doing so by some mechanism other than its selective uptake the Radiosynthesis Laboratory, Division of Medicinal Chemistry and Natural Into normal tissue and subsequent nonspecific inactivation of any reactive Products, School of Pharmacy, at the University of North Carolina at Chapel cytosolic platinum species formed. Other possible mechanisms are briefly Hill with a specific activity of 0.520 Ci/mmol. The synthesis and purity of this compound have been described elsewhere (20). Reductive tritiation of the cyclohexene ring yields a radiolabel that is not chemically exchangeable (20). INTRODUCTION Preparation of a solution of the drug for administration was as described previously (14). WR-2721 and its corresponding free thiol, WR-1065, were WR-27213 is a phosphorothioate compound currently in Phase III obtained from US Bioscience (West Conshohocken, PA). This is different clinical trials investigating its efficacy at reducing the adverse side from the clinical formulation available through the National Cancer Institute, effects of both radiotherapy and alkylating agent chemotherapy of which contains a 1:1 mix by weight of WR-2721 and mannitol. The drug was neoplastic disease (1—3).This chemoprotective effect is purported to dissolved either in H20 (20 mg/ml) for i.p. injection or in PBS (pH 7.5; 100 mg/mi) for iv. injection and filtered immediately before use. YMT ultrafil tration membranes (M, cutoff, 30,000) were purchased from Amicon (Danvers, Received 2/6/95; accepted 5/3/95. Thecostsof publicationofthisarticleweredefrayedinpartby thepaymentofpage MA). HPLC grade reagents were obtained from commercial sources, and charges. This article must therefore be hereby marked advertisement in accordance with solutions were filtered and degassed before use. A Barnstead Nanopure water 18 U.S.C. Section 1734 solely to indicate this fact. purification system with an organics filter provided the water used with I This work was supported by NIH Grants CA55326 and ES07126. solvents and for dissolution. All other general laboratory reagents were com 2 To whom requests for reprints should be addressed, at Department of Biochemistry and Biophysics, 502 FLOB CB# 7260, University of North Carolina, Chapel Hill, NC mercial reagent grade or better and were used without additional purification. 27599-7260. Animals. Male Fischer 344 adult rats (150—200 g) were obtained from 3 ‘FIse abbreviations and trivial names used are: WR-2721, S-2-(3-aminopropyl Charles River Breeding Laboratories (Raleigh, NC) and housed in clear plastic amino)ethylphosphorothioicacid(Ethiofos,Amifostine,Ethyol);WR-1065,S-2-(3-ami cages on a 12-h light/12-h dark cycle with access to water and Purina rodent nopropylamino)ethanethiol, the thiol metabolite of WR-2721; cisplatin, cis [PtCl2(NH3)2J, cis-diamminedichloroplatinum(!I) (cDDP); ormaplatin (formerly called chow ad libitum. Room temperature was maintained at approximately 22°C. tetraplatin), (d@l)trans-1,2-diaminocyclohexanetetrachloroplatinum(!V);dach,(d,l)trans Animals were allowed at least a 1-week acclimatization period before use in 1,2-diaminocyclohexane; Pt(dach)Cl2, (cU)trans-1,2-diaminocyclohexanedichloroplati experiments. A transplantable fibrosarcoma (originally induced by methylchol num(ll); P2, reverse phase; SCX, strong cation exchange chromatography; AAS, flame anthrene) was obtained from Dr. M. W. Dewhirst (Duke University Medical less atomic absorption spectroscopy; LSC, liquid scintillation counting; GSH, reduced glutathione. Platinum(II) complexes with various amino acids are indicated as: Pt Center, Durham, NC) with permission from Dr. J. M. C. Bull (University of (dachXaminoacid)orPt(aminoacid)@;inmostcases,theexactstoichiometryorchargeof Texas Health Science Center, Houston, TX), who originally developed the the complex is not known. tumor (21). The tumor was maintained via regular passage involving s.c. hind 2837 Downloaded from cancerres.aacrjournals.org on September 25, 2021. © 1995 American Association for Cancer Research. WR-2721 AND ORMAPLATIN BIOTRANSFORMATIONSIN F344 RATS flank implantation of solid donor tumor (“100mm3) under ketamine-xylazine material, the reaction products formed were identical.4 Henceforth, only the anesthesia. Experiments were routinely performed at 10 days posttransplanta Pt(dach)(WR-1065) was used in column standardization, along with the other tion, at which time tumor volume was on average 2.5—3.0cm3. standards routinely tested: Pt(dach@cysteine),Pt(dachXGSH),Pt(dachXmethi Methods. Animals were administered WR-2721 or corresponding vehicle onine), Pt(dachXserine),and the free dach ligand. These were the standards the by either of two protocols. For most of the experiments, a dual i.p. paradigm chromatographic characteristics of which most closely approximated those of was used, in which case the WR-2721 (20 mg/mI and 200 mg/kg; @34-fold the RP HPLC peaks that appeared routinely in greatest abundance in the molar excess to platinum on a per kg body weight basis) or H20 vehicle was biological samples. administered i.p. under light ether anesthesia at time zero (4). At t 30 mm, Statistics. Independent (unpaired) t tests on control (ormaplatin only) ormaplatin was administered (12.5 mg/kg, i.p.), also under light ether anes and treated (WR-2721 plus ormaplatin) variables were performed with the thesia. These animals were all then sacrificed at t = 60 mm. The second SYSTAT statisticalpackage (SYSTAT, Inc., Evanston,IL). Assessment of the significance of any effect of WR-2721 treatment on ormaplatin disposition protocol used an i.v./i.p. paradigm in which the WR-2721 (100 mg/ml in PBS, or biotransformation was at the P = 0.05 level. pH 7.5 vehicle, 200 mg/kg) was administered iv. via the lateral vein under light ether anesthesia at time zero. For this protocol, ormaplatin (12.5 mg/kg i.p.) was administered at either t = 5 mm or t = 30 mm. These animals were RESULTS then sacrificed at either 15, 30, or 60 mm after ormaplatin administration.